Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ginkgo Bioworks Holdings

Teladoc

These stocks aren't for the faint of heart.

Cathie Wood Is Loading Up on These 3 Stocks: Should You?

DraftKings

Roblox

Verve Therapeutics

It's been a difficult year for Cathie Wood stocks and exchange-traded funds, as the ARK Innovation ETF (NYSEARCA: ARKK ) has lost over 50% of its market capitalization. The losses have been driven by supply chain inefficiencies, inflation, and subsequent interest hikes to combat inflation.

5 Top Stocks Cathie Wood Is Buying Right Now

Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).

Intellia (NTLA) Reports Positive Results for CRISPR Candidates

CRISPR Therapeutics

These biotech companies will either sink or swim before the end of the decade.

2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years

AMC Entertainment

ARK Innovation ETF

Block

Sizzling inflation that helped send 2-year U.S. Treasury yields to fresh 14-year highs continued to burn some of the winners of the so-called pandemic bubble Friday.

'The selling pressure is feeding on itself:' ARK, meme stocks tumble as Fed hike looms

Source: Shutterstock Intellia Therapeutics (NASDAQ: NTLA ) stock is on the move Friday after releasing positive clinical trial data for two of its drugs. NTLA-2002 is the first drug behind NTLA stock movement today.

What Is Going on With Intellia Therapeutics (NTLA) Stock Today?

Shares of Intellia Therapeutics Inc. NTLA, +7.36% gained 6.5% in premarket trading on Friday after the company and Regeneron Pharmaceuticals Inc. REGN, +1.18% announced positive data from an ongoing Phase 1 clinical trial evaluating their investigational Crispr therapy as a treatment for transthyretin amyloidosis with cardiomyopathy, which can cause heart failure. The data demonstrated a reduction in serum transthyretin in 12 patients for up to six months.

Intellia's stock is up 6% on data from an early-stage trial for its Crispr therapy

Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. The update could send CRISPR stocks flying.

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing

Regeneron Pharmaceuticals

Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28  NTLA-2001 was generally well-tolerated at both dose levels Intellia to discuss data at investor event today, Friday, September 16, at 8:00 a.m. ET CAMBRIDGE, Mass.

Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced positive interim results from an ongoing Phase 1/2 clinical study of NTLA-2002, its second in vivo genome editing candidate. NTLA-2002 is a systemically administered CRISPR candidate being developed for hereditary angioedema (HAE) and is designed to knock out the KLKB1 gene in liver cells, thereby reducing the production of kallikrein protein. Uncontrolled activity of kallikrein is responsible for the overproduction of bradykinin, which leads to the recurring, debilitating and potentially fatal swelling attacks that occur in people living with HAE. The interim data were shared today in an oral presentation at the 2022 Bradykinin Symposium held in Berlin, Germany.

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

SparingVision Raises € 75 M illion Series B to Continue Building World-Leading Portfolio of G enomic M edicine s for O cular D isease s

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

SparingVision lève 75 millions d'euros pour accélérer le développement de son portefeuille de produits de médecine génomique  en ophtalmologie

SparingVision lève 75 millions d'euros pour accélérer le développement de son portefeuille de produits de médecine génomique en ophtalmologie

CAMBRIDGE, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that it will host a virtual investor event to present interim data from the first-in-human clinical studies of NTLA-2002 and NTLA-2001 on September 16, 2022, at 8:00 a.m. ET.

Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia's in vivo CRISPR/Cas9 genome editing candidate, NTLA-2002, for the treatment of hereditary angioedema (HAE).

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Alnylam Pharmaceuticals

Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR.

Can Intellia One-Up Alnylam In Transthyretin Amyloidosis?

CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract featuring interim clinical data from the Phase 1/2 study of NTLA-2002 has been selected for an oral presentation at the 2022 Bradykinin Symposium, taking place September 15-16 in Berlin, Germany. NTLA-2002 is an investigational in vivo CRISPR/Cas9 therapy in development as a single-dose treatment to prevent angioedema attacks in people living with hereditary angioedema (HAE). The presentation will include interim safety, kallikrein reduction and attack rate data from the ongoing dose-escalation portion of Intellia's first-in-human study of NTLA-2002.

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium

Apellis Pharma

Beam Therapeutics

Chemocentryx

Fate Therapeutics

Global Blood Therapeutics

Karuna Therapeutics Inc

PTC Therapeutics

Repligen

Twist Bioscience Corp

Barron's screened for stocks such as Global Blood Therapeutics and Karuna Therapeutics that popped this summer.

10 Stocks Driving the Biotech Resurgence

New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Intellia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA

AppLovin Corp

Digital Turbine

Bausch Health Companies Inc

Farfetch

Warner Bros Discovery Inc

Generally, Wall Street stock price predictions are hardly the best source of investing ideas that have the most upside. Investors should interpret stocks that analysts claim have the most upside carefully.

7 Stock Price Predictions That Are Actually Worth Listening To

Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2022 Results Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor Relations and Corporate Communications John Leonard - President and Chief Executive Officer David Lebwohl - Executive Vice President and Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President and Chief Scientific Officer Glenn Goddard - Executive Vice President and Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Maury Raycroft - Jefferies Dae Gon Ha - Stifel Gena Wang - Barclays Joseph Thome - Cowen and Company Swapnil Malekar - Piper Sandler Salveen Richter - Goldman Sachs Luca Issi - RBC Capital Markets Richard Law - Credit Suisse Greg Harrison - Bank of America Mani Foroohar - SVB Leerink Jay Olson - Oppenheimer & Co. Ry Forseth - Guggenheim Partners Kostas Biliouris - BMO Capital Markets Yanan Zhu - Wells Fargo Operator Good morning. And welcome to the Intellia Therapeutics' Second Quarter 2022 Financial Results Conference Call.

Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q2 2022 Results - Earnings Call Transcript

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple. The post Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned appeared first on Investor's Business Daily.

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

Investors are reacting negatively to the company's Q2 update.

Why Intellia Therapeutics Stock Is Sinking Today

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -1.53% and 21.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the second quarter ended June 30, 2022.

News for Intellia Therapeutics Stock (NTLA)